A Phase III Clinical Trial of Buserelin versus Danazol in the Treatment of Endometriosis

W Matta, Robert W. Shaw
In: GnRH Analogues in Cancer and Human Reproduction · 1990 · pp. 39–42 · doi:10.1007/978-94-009-2169-6_5 · W4249545935
book-chapter OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-07-28 ⓘ

This phase III trial investigated whether buserelin, a GnRH agonist causing hypoestrogenism, was superior to danazol for treating endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-10 · read from full text ⓘ

This Phase III clinical trial directly compared the efficacy of the GnRH agonist buserelin against danazol for treating endometriosis, operating on the hypothesis that suppressing pituitary-ovarian function to induce hypo-oestrogenism is superior to inducing a pseudopregnancy state. The study evaluated how this hormonal suppression led to the atrophy and regression of endometriotic tissue in patients undergoing treatment. While the paper focuses on these comparative outcomes, it implicitly acknowledges limitations related to bone density effects associated with hypogonadism as seen in related literature cited by the authors. This paper is centrally about endometriosis — specifically comparing two distinct hormonal treatment modalities for managing the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,280 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Hormonal treatments for endometriosis which are aimed at suppressing the pituitary-ovarian function (‘pseudomenopause’) seem to be superior to those regimes aimed at inducing a ‘pseudopregnancy’ state. Hypo-oestrogenism can cause atrophy and regression of endometriotic tissue. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

References

Barbieri, RL, Evans, S and Kistner, RW (1982). Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril, 37, 737 Lemay, A, Maheux, R, Faure, N, Jean, C and Fazekas, ATA (1984). Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil Steril, 41, 863 Shaw, RW and Matta, WHM (1986). Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis — comparison of two dose regimens. Clin Reprod Fertil, 4, 329 Revised American Fertility Society Classification of Endometriosis (1985). Fertil Steril, 43, 351 Matta, WHM, Shaw, RW, Hesp, R and Katz, D (1987). Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects of bone density in premenopausal women. Brit Med J, 294, 1523 Author information Authors and Affiliations Editor information Editors and Affiliations Rights and permissions Copyright information © 1990 Springer Science+Business Media Dordrecht About this chapter Cite this chapter Matta, W.H.M., Shaw, R.W. (1990). A Phase III Clinical Trial of Buserelin versus Danazol in the Treatment of Endometriosis. In: Vickery, B.H., Lunenfeld, B. (eds) GnRH Analogues in Cancer and Human Reproduction. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-2169-6_5 Download citation DOI: https://doi.org/10.1007/978-94-009-2169-6_5 Publisher Name: Springer, Dordrecht Print ISBN: 978-94-010-7474-2 Online ISBN: 978-94-009-2169-6 eBook Packages: Springer Book Archive

Keywords

- GnRH Agonist - Endometriotic Lesion - Endometriotic Tissue - Cortical Bone Mineral Content - Revise American Fertility Society These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (5)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-20T06:29:17.529187+00:00
License: CC0 · commercial use OK